EDASALONEXENT ( DrugBank: Edasalonexent )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 113 | 筋ジストロフィー | 11 |
113. 筋ジストロフィー
臨床試験数 : 646 / 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04322357 (ClinicalTrials.gov) | July 30, 2020 | 24/3/2020 | Weekend Steroids and Exercise as Therapy for DMD | Impact and Interplay of Corticosteroid Regimen and Exercise Training on DMD Muscle Function | Duchenne Muscular Dystrophy (DMD) | Drug: Prednisone;Behavioral: In-home Exercise Training;Drug: Prednisone with daily edasalonexent;Drug: Prednisone plus exercise | University of Florida | U.S. Army Medical Research and Development Command;Catabasis Pharmaceuticals | Recruiting | 5 Years | 8 Years | Male | 89 | Phase 2 | United States |
| 2 | EUCTR2019-003563-22-IE (EUCTR) | 23/06/2020 | 21/01/2020 | A study to provide Edasalonexent to Pediatric Patients with Duchenne Muscular Dystrophy | An Open-Label Extension Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: Edasalonexent Product Code: CAT-1004 INN or Proposed INN: EDASALONEXENT | Catabasis Pharmaceuticals Inc. | NULL | Not Recruiting | Female: no Male: yes | 140 | Phase 3 | United States;Canada;Ireland;Australia;Germany;United Kingdom;Sweden | ||
| 3 | EUCTR2019-003563-22-GB (EUCTR) | 23/04/2020 | 13/01/2020 | A study to provide Edasalonexent to Pediatric Patients with Duchenne Muscular Dystrophy | An Open-Label Extension Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy - An Open-Label Extension Study of Edasalonexent in DMD Patients | Duchenne Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: Edasalonexent Product Code: CAT-1004 INN or Proposed INN: EDASALONEXENT | Catabasis Pharmaceuticals Inc. | NULL | Not Recruiting | Female: no Male: yes | 140 | Phase 3 | United States;Canada;Ireland;Australia;Germany;United Kingdom;Sweden | ||
| 4 | EUCTR2019-003563-22-DE (EUCTR) | 16/04/2020 | 31/01/2020 | A study to provide Edasalonexent to Pediatric Patients with Duchenne Muscular Dystrophy | An Open-Label Extension Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: Edasalonexent Product Code: CAT-1004 INN or Proposed INN: EDASALONEXENT | Catabasis Pharmaceuticals Inc. | NULL | Not Recruiting | Female: no Male: yes | 140 | Phase 3 | United States;Canada;Ireland;Australia;Israel;Germany;United Kingdom;Sweden | ||
| 5 | EUCTR2019-003563-22-SE (EUCTR) | 15/04/2020 | 03/02/2020 | A study to provide Edasalonexent to Pediatric Patients with Duchenne Muscular Dystrophy | An Open-Label Extension Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: Edasalonexent Product Code: CAT-1004 INN or Proposed INN: EDASALONEXENT | Catabasis Pharmaceuticals Inc. | NULL | Not Recruiting | Female: no Male: yes | 140 | Phase 3 | United States;Canada;Ireland;Australia;Germany;United Kingdom;Sweden | ||
| 6 | NCT03917719 (ClinicalTrials.gov) | March 14, 2019 | 12/4/2019 | An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy | An Open-Label Extension Study of Edasalonexent in Pediatric Patients With Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy | Drug: Edasalonexent | Catabasis Pharmaceuticals | NULL | Terminated | 4 Years | 12 Years | Male | 130 | Phase 3 | United States;Australia;Canada;Germany;Sweden;United Kingdom |
| 7 | EUCTR2018-000464-29-DE (EUCTR) | 31/01/2019 | 24/09/2018 | A study to compare edasalonexent with placebo in patients with Duchenne Muscular dystrophy | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, GLOBAL PHASE 3 STUDY OF EDASALONEXENT IN PEDIATRIC PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY - POLARIS DMD | Duchenne muscular dystrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: Edasalonexent Product Code: CAT-1004 INN or Proposed INN: EDASALONEXENT Product Name: Edasalonexent Product Code: CAT-1004 INN or Proposed INN: EDASALONEXENT | Catabasis Pharmaceuticals, Inc. | NULL | Not Recruiting | Female: no Male: yes | 126 | Phase 3 | United States;Canada;Ireland;Australia;Israel;Germany;United Kingdom;Sweden | ||
| 8 | EUCTR2018-000464-29-IE (EUCTR) | 16/01/2019 | 02/10/2018 | A study to compare edasalonexent with placebo in pediatric patients with Duchenne Muscular dystrophy. | A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, GLOBAL PHASE 3 STUDY OFEDASALONEXENT IN PEDIATRIC PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY - Phase 3 Study of Edasalonexent in Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: Edasalonexent Product Code: CAT-1004 INN or Proposed INN: Edasalonexent | Catabasis Pharmaceuticals, Inc. | NULL | Not Recruiting | Female: no Male: yes | 126 | Phase 3 | United States;Canada;Ireland;Australia;Israel;Germany;United Kingdom;Sweden | ||
| 9 | EUCTR2018-000464-29-SE (EUCTR) | 11/12/2018 | 24/09/2018 | A study to compare edasalonexent with placebo in patients with Duchenne Muscular dystrophy. | A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, GLOBAL PHASE 3 STUDY OFEDASALONEXENT IN PEDIATRIC PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY - POLARIS DMD | Duchenne Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: Edasalonexent Product Code: CAT-1004 INN or Proposed INN: Edasalonexent | Catabasis Pharmaceuticals, Inc. | NULL | Not Recruiting | Female: no Male: yes | 126 | Phase 3 | Canada;Ireland;Australia;Israel;Germany;United Kingdom;Sweden;United States | ||
| 10 | NCT03703882 (ClinicalTrials.gov) | October 2, 2018 | 8/10/2018 | Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy | A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients With Duchenne Muscular Dystrophy | Muscular Dystrophy, Duchenne | Drug: Edasalonexent;Drug: Placebo | Catabasis Pharmaceuticals | NULL | Completed | 4 Years | 7 Years | Male | 131 | Phase 3 | United States;Australia;Canada;Germany;Ireland;Israel;Sweden;United Kingdom |
| 11 | NCT02439216 (ClinicalTrials.gov) | April 2016 | 29/4/2015 | Phase 1/2 Study in Boys With Duchenne Muscular Dystrophy | A Phase 1/2 Study of Edasalonexent (CAT-1004) in Pediatric Patients With Duchenne Muscular Dystrophy | Muscular Dystrophy, Duchenne | Drug: Edasalonexent;Drug: Placebo | Catabasis Pharmaceuticals | NULL | Completed | 4 Years | 7 Years | Male | 31 | Phase 1/Phase 2 | United States |